Engineering LNPs with polysarcosine lipids for mRNA delivery

Diana D. Kang,Xucheng Hou, Leiming Wang,Yonger Xue, Haoyuan Li,Yichen Zhong, Siyu Wang,Binbin Deng, David W. McComb,Yizhou Dong

BIOACTIVE MATERIALS(2024)

引用 0|浏览5
暂无评分
摘要
Since the approval of the lipid nanoparticles (LNP)-mRNA vaccines against the SARS-CoV-2 virus, there has been an increased interest in the delivery of mRNA through LNPs. However, current LNP formulations contain PEG lipids, which can stimulate the generation of anti-PEG antibodies. The presence of these antibodies can potentially cause adverse reactions and reduce therapeutic efficacy after administration. Given the widespread deployment of the COVID-19 vaccines, the increased exposure to PEG may necessitate the evaluation of alternative LNP formulations without PEG components. In this study, we investigated a series of polysarcosine (pSar) lipids as alternatives to the PEG lipids to determine whether pSar lipids could still provide the functionality of the PEG lipids in the ALC-0315 and SM-102 LNP systems. We found that complete replacement of the PEG lipid with a pSar lipid can increase or maintain mRNA delivery efficiency and exhibit similar safety profiles in vivo.
更多
查看译文
关键词
Lipid nanoparticles,mRNA,Polyethylene glycol (PEG),Polysarcosine (pSar)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要